To understand whether AICAR’s effects are dependent upon EGFR mutations, we tested drug response in another panel of lung cancer cells with wild-type EGFR, including H358, H23, H441, A549, and H69 (Fig. 1b). The gene discussed is EGFR; the disease is lung carcinoma.